NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
Clinical Trials
8 trialsNCT06977061 2025-05-16
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Second Affiliated Hospital of Nanchang University
Phase 2/3 Not yet recruiting
NCT05250843 2023-10-13
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2/3 Unknown
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT05322187 2022-04-11
sPLENTY-pc
RenJi Hospital
Phase 2/3 Unknown
NCT05002686 2021-08-24
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Ruijin Hospital
Phase 2/3 Unknown
NCT04167293 2021-03-23
ISBRT01
Sun Yat-sen University
Phase 2/3 Unknown
NCT04192682 2020-01-06
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Changzhou Cancer Hospital of Soochow University
Phase 2/3 Unknown